How to buy Strongbridge Biopharma stock

Strongbridge Biopharma plc is a biotechnology business based in the US. Strongbridge Biopharma shares (SBBP) are listed on the NASDAQ and all prices are listed in US Dollars. Strongbridge Biopharma employs 72 staff and has a trailing 12-month revenue of around 0.00.

Strongbridge Biopharma share price

Use our graph to track the performance of SBBP stocks over time.

Strongbridge Biopharma shares at a glance

• Key figures

Information last updated 2021-03-10.

52-week range	$1.50 - $4.44
50-day moving average	$3.09
200-day moving average	$2.70
Wall St. target price	$8.00
PE ratio	4.2673
Dividend yield	N/A (0%)
Earnings per share (TTM)	$0.62

Buy Strongbridge Biopharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Strongbridge Biopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Strongbridge Biopharma plc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Strongbridge Biopharma under- or over-valued?

Valuing Strongbridge Biopharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Strongbridge Biopharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Strongbridge Biopharma's P/E ratio

Strongbridge Biopharma's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 4x. In other words, Strongbridge Biopharma shares trade at around 4x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Strongbridge Biopharma financials

Revenue TTM	$30.7 million
Gross profit TTM	$28.5 million
Return on assets TTM	-22.43%
Return on equity TTM	-65.42%
Profit margin	-146.68%
Book value	$0.98
Market capitalisation	$196.1 million

TTM: trailing 12 months

Shorting Strongbridge Biopharma shares

There are currently 593,370 Strongbridge Biopharma shares held short by investors – that's known as Strongbridge Biopharma's "short interest". This figure is 14.6% down from 694,462 last month.

There are a few different ways that this level of interest in shorting Strongbridge Biopharma shares can be evaluated.

Strongbridge Biopharma's "short interest ratio" (SIR)

Strongbridge Biopharma's "short interest ratio" (SIR) is the quantity of Strongbridge Biopharma shares currently shorted divided by the average quantity of Strongbridge Biopharma shares traded daily (recently around 1.1 million). Strongbridge Biopharma's SIR currently stands at 0.56. In other words for every 100,000 Strongbridge Biopharma shares traded daily on the market, roughly 560 shares are currently held short.

However Strongbridge Biopharma's short interest can also be evaluated against the total number of Strongbridge Biopharma shares, or, against the total number of tradable Strongbridge Biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Strongbridge Biopharma's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Strongbridge Biopharma shares in existence, roughly 10 shares are currently held short) or 0.0105% of the tradable shares (for every 100,000 tradable Strongbridge Biopharma shares, roughly 11 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Strongbridge Biopharma.

Find out more about how you can short Strongbridge Biopharma stock.

Strongbridge Biopharma share dividends

We're not expecting Strongbridge Biopharma to pay a dividend over the next 12 months.

Strongbridge Biopharma share price volatility

Over the last 12 months, Strongbridge Biopharma's shares have ranged in value from as little as $1.5 up to $4.44. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Strongbridge Biopharma's is 1.7205. This would suggest that Strongbridge Biopharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Strongbridge Biopharma overview

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company offers Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trials that for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is headquartered in Trevose, Pennsylvania. .

Frequently asked questions

• What percentage of Strongbridge Biopharma is owned by insiders or institutions?

  Currently 9.105% of Strongbridge Biopharma shares are held by insiders and 71.178% by institutions.

• How many people work for Strongbridge Biopharma?

  Latest data suggests 72 work at Strongbridge Biopharma.

• When does the fiscal year end for Strongbridge Biopharma?

  Strongbridge Biopharma's fiscal year ends in December.

• Where is Strongbridge Biopharma based?

  Strongbridge Biopharma's address is: 900 Northbrook Drive, Trevose, PA, United States, 19053

• What is Strongbridge Biopharma's ISIN number?

  Strongbridge Biopharma's international securities identification number is: IE00BYZ5XL97

• What is Strongbridge Biopharma's CUSIP number?

  Strongbridge Biopharma's Committee on Uniform Securities Identification Procedures number is: G85347105